NZ, I think the comments in the link below partially explain your concerns regarding the company’s lack of PR.
https://parkinsonsnewstoday.com/2017/10/04/parkinsons-hopes-raised-dashed-more-research/
LCT are on the brink of potentially making an announcement that ends in “we’re now open for business” instead of “although more research needs to be done”.
I think the company have done a reasonable PR job with the LCT story picked up by several international mainstream publications in June that will no doubt be closely following the trial progress.
I’m confident these publications, as well as others who will pick up the story based on more definitive results along with the huge spike in investor interest recently will ensure that the company will receive the publicity and market valuation proportionate to the trial outcome next month.
LCT Price at posting:
23.0¢ Sentiment: Buy Disclosure: Held
